DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0268722 A1 Siegelin Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 20110268722A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0268722 A1 Siegelin et al. (43) Pub. Date: Nov. 3, 2011 (54) COMBINATION THERAPIES WITH Publication Classification MTOCHONORAL-TARGETED (51) Int. Cl ANT-TUMIORAGENTS A638/17 (2006.01) CI2N 5/071 (2010.01) (76) Inventors: Markus D. Siegelin, Weehawken, A6IP35/00 (2006.01) NJ (US); Dario C. Altieri, A 6LX 39/395 (2006.01) Worcester, MA (US) C07D 225/06 (2006.01) (52) U.S. Cl. ..................... 424/130.1; 514/18.9; 540/461; (21) Appl. No.: 13/092,475 435/375 (57) ABSTRACT (22) Filed: Apr. 22, 2011 Described are mitochondria-targeted anti-tumor agents, death receptor agonists, autophagy inhibitors, and NF-KB Related U.S. Application Data signaling pathway inhibitors, and methods of making and (60) Provisional application No. 61/326,872, filed on Apr. using the same for the treatment of disorders associated with 22, 2010. unwanted cell proliferation. Patent Application Publication Nov. 3, 2011 Sheet 1 of 13 US 2011/0268722 A1 120% 8: 8: 8 CE 60% : 5 P_GA s : RA 2:: : P-GA-RA : : 8 N3 FAS Figure 1A Patent Application Publication Nov. 3, 2011 Sheet 2 of 13 US 2011/0268722 A1 igure 1B ---, igure 2A Figure 2B Patent Application Publication Nov. 3, 2011 Sheet 3 of 13 US 2011/0268722 A1 8. s::::::: se: -83.383.3 ---sixxxxx:----- --~~~x-x-x-xxii. : s: 8 i88 s: sig ::::::: ...i Figure 2C Figure 2D Figure 3A Figure 3B Patent Application Publication Nov. 3, 2011 Sheet 4 of 13 US 2011/0268722 A1 ::: :*:: & : : isix; {S3.g3-8 : Exx8:8-3 : {kari 333333. ::::: :: 3 8: 8 : x : x: 88: : S. 8 st::::: 34 gas $3. Figure 3D Patent Application Publication Nov. 3, 2011 Sheet 5 of 13 US 2011/0268722 A1 . f w i i : f Days O S 8 7 8 a death Figure 4 eige exte: vehicle PBS es s: RA -3- 888; 3. Figure 5A Patent Application Publication Nov. 3, 2011 Sheet 6 of 13 US 2011/0268722 A1 388838: After treatert Air: - -3.3888-89: & 8 223-8-3-3F 3888: '3's vehicle (PBS R & R& Ras 888 8 s. 3.88-3 as . .38F Figure 5B 25x100 20x1007 5x100 0x007 5.0x 106 Figure 6A Patent Application Publication Nov. 3, 2011 Sheet 7 of 13 US 2011/0268722 A1 ge:38 x 18 8. Ox of 8.0x108 40x1087 2x 18 Figure 6B 50 an Vehicle sks RA 100 ...s. pp x RA-PP 50 ine Figure 7 Patent Application Publication Nov. 3, 2011 Sheet 8 of 13 US 2011/0268722 A1 Figure 8 Patent Application Publication Nov. 3, 2011 Sheet 9 of 13 US 2011/0268722 A1 Figure 9 Patent Application Publication Nov. 3, 2011 Sheet 10 of 13 US 2011/0268722 A1 inst Figure 10 A. B C G Target siRNA 2. - as 100 7 E 53 3 25 . Ctraig5 (Ctrl ag5 Figure 11 B Figure 12 Patent Application Publication Nov. 3, 2011 Sheet 11 of 13 US 2011/0268722 A1 A 3. 2 8. Figure 13 A B 6 15 as & 4 10 2 E 5 i. 17AAC 7AA Figure 14 Patent Application Publication Nov. 3, 2011 Sheet 12 of 13 US 2011/0268722 A1 A B Citri siRNA target siRNA N Ox& xS& occces c lcHOP -acti Fores is st s's 8 ss& NF -- Fig. Figure 15 Target cMA Figure 16 Patent Application Publication Nov. 3, 2011 Sheet 13 of 13 US 2011/0268722 A1 Figure 17 US 2011/0268722 A1 Nov. 3, 2011 COMBINATION THERAPES WITH 0006. Also provided are methods of treating of a prolif MTOCHONORAL-TARGETED erative disorder in a Subject that include administering to the ANT-TUMIORAGENTS Subject at least one mitochondrial-targeted chaperone inhibi tor and at least one agent selected from the group of a death CROSS-REFERENCE TO RELATED receptor agonist, an autophagy inhibitor, and a NF-KB Sig APPLICATIONS naling pathway inhibitor, where the at least one mitochon 0001. This application claims priority to U.S. provisional drial-targeted chaperone inhibitor and the at least one agent application 61/326,872, filed Apr. 22, 2010, the contents of are administered in an amount Sufficient to treat of a prolif each of which are incorporated herein by reference in their erative disorder in the subject. entirety. 0007 Also provided are methods for enhancing cancer or tumor cell death that include administering to the Subject at TECHNICAL FIELD least one mitochondrial-targeted chaperone inhibitor and at 0002. This invention relates to the use of at least one mito least one agent selected from the group of a death receptor chondria-targeted inhibitor of molecular chaperones in com agonist, an autophagy inhibitor, and a NF-KB signaling path bination with one or more death receptoragonists, autophagy way inhibitor, where the at least one mitochondrial-targeted inhibitors, and/or NF-kB signaling pathway inhibitors for the chaperone inhibitor and the at least one agent are adminis treatment of disorders associated with unwanted cell prolif tered in an amount Sufficient to enhance cancer or tumor cell eration. death in a Subject. 0008. Some embodiments of the methods described BACKGROUND hereinfurther include identifying a subject having cancer or a 0003 Tumor cells exhibit an enhanced ability to survive tumor and/or determining whether cells of the cancer or and proliferate in highly unfavorable environments. They tumor have increased mitochondrial concentrations of a have been shown to down-regulate many of the cellular path chaperone as compared to a control cell. In some embodi ways that prevent normal (i.e., non-cancerous) cells from ments of the methods described herein, the at least one mito dividing in a hostile environment, and they also inactivate chondrial-targeted chaperone inhibitor and the at least one apoptotic pathways that bring about cell death in many nor agent are administered simultaneously to the Subject. In some mal tissues under adverse conditions. Tumor cells are also embodiments of the methods described herein, theat least one believed to up-regulate pathways required to maintain active agent is administered to the subject prior to the at least one proliferation. For example, many tumor cells activate the mitochondrial-targeted chaperone inhibitor, or the at least cellular stress-response pathway that allows tumor cells to one mitochondrial-targeted chaperone inhibitor is adminis synthesize and maintain the protein machinery they need to tered to the Subject prior to the at least one agent. In some continue proliferating. The activated stress response in embodiments of all of the methods described herein, the tumors includes up-regulation of heat-shock proteins (Hsps), proliferative disorder is a cancer (e.g., a cancer selected from which are ATPase-directed molecular chaperones. In particu the group of Small-cell lung cancer, non-Small cell lung can lar, Hsp90 is upregulated in many cancerous tissues. Hsp90 cer, colon cancer, colorectal cancer, and pancreatic cancer). controls the balance between folding/maturation and protea Somal destruction of a restricted number of client proteins, 0009. Also provided are methods of treating atherapeutic Some of which are involved in signal transduction and cell resistant cancer in a subject that include administering to a proliferation. Subject having cancer cells resistant to a cancer therapeutic at least one mitochondrial-targeted chaperone inhibitor and the SUMMARY cancer therapeutic, where the at least one mitochondrial targeted chaperone inhibitor and the cancer therapeutic are 0004. The present invention is based, at least in part, on the administered in amount Sufficient to treat the therapeutic discovery that inhibition of molecular chaperones in tumor resistant cancer. Some embodiments of these methods, fur cell mitochondria using mitochondrial-targeted chaperone ther comprise identifying a subject as having a therapeutic inhibitors potentiated the effect of death receptor agonists to resistant cancer. In some embodiments, the Subject is induce cell death, e.g., in cancer cells, and that mitochondrial identified by detecting an increase in NF-KB signaling activ targeted chaperone inhibitors induce autophagy and decrease NF-KB signaling pathway activity in cancer cells. ity in a cancer cell in the Subject. 0005 Provided herein are methods of enhancing apoptosis 0010 Also provided is the use of at least one mitochon in one or more mammalian cells that include contacting the drial-targeted chaperone inhibitor for the preparation of a one or more cells with at least one mitochondrial-targeted medicament for treatment of a proliferative disorder. Also chaperone inhibitor and at least one agent selected from the provided is the use of at least one death receptor agonist, group of a death receptor agonist, an autophagy inhibitor, autophagy inhibitor, and NF-KB signaling pathway inhibitor and a NF-kB signaling pathway inhibitor, where the at least in the preparation of a medicament for treatment of a prolif one mitochondrial-targeted chaperone inhibitor and the at erative disorder, characterized in that the treatment includes least one agent are in an amount Sufficient to enhance apop administering at least one mitochondrial-targeted chaperone tosis in the one or more cells. In some embodiments, the one inhibitor. Also provided is the use of at least one mitochon or more cells are contacted sequentially with the at least one drial-targeted chaperone inhibitor in the preparation of a mitochondrial-targeted chaperone inhibitor and the at least medicament for treatment of a proliferative disorder, charac one agent. In some embodiments, the one or more cells are terized in that the treatment includes administering at least contacted simultaneously with the at least one mitochondrial one death receptor agonist, autophagy inhibitor, and NF-KB targeted chaperone inhibitor and the at least one agent. signaling pathway inhibitor. US 2011/0268722 A1 Nov.
Recommended publications
  • Integrating Complementary Medicine Into Cardiovascular Medicine

    Integrating Complementary Medicine Into Cardiovascular Medicine

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Journal of the American College of Cardiology Vol. 46, No. 1, 2005 © 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.031 ACCF COMPLEMENTARY MEDICINE EXPERT CONSENSUS DOCUMENT Integrating Complementary Medicine Into Cardiovascular Medicine A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine) WRITING COMMITTEE MEMBERS JOHN H. K. VOGEL, MD, MACC, Chair STEVEN F. BOLLING, MD, FACC BRIAN OLSHANSKY, MD, FACC REBECCA B. COSTELLO, PHD KENNETH R. PELLETIER, MD(HC), PHD ERMINIA M. GUARNERI, MD, FACC CYNTHIA M. TRACY, MD, FACC MITCHELL W. KRUCOFF, MD, FACC, FCCP ROBERT A. VOGEL, MD, FACC JOHN C. LONGHURST, MD, PHD, FACC TASK FORCE MEMBERS ROBERT A. VOGEL, MD, FACC, Chair JONATHAN ABRAMS, MD, FACC SANJIV KAUL, MBBS, FACC JEFFREY L. ANDERSON, MD, FACC ROBERT C. LICHTENBERG, MD, FACC ERIC R. BATES, MD, FACC JONATHAN R. LINDNER, MD, FACC BRUCE R. BRODIE, MD, FACC* ROBERT A. O’ROURKE, MD, FACC† CINDY L. GRINES, MD, FACC GERALD M. POHOST, MD, FACC PETER G. DANIAS, MD, PHD, FACC* RICHARD S. SCHOFIELD, MD, FACC GABRIEL GREGORATOS, MD, FACC* SAMUEL J. SHUBROOKS, MD, FACC MARK A. HLATKY, MD, FACC CYNTHIA M. TRACY, MD, FACC* JUDITH S. HOCHMAN, MD, FACC* WILLIAM L. WINTERS, JR, MD, MACC* *Former members of Task Force; †Former chair of Task Force The recommendations set forth in this report are those of the Writing Committee and do not necessarily reflect the official position of the American College of Cardiology Foundation.
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • Investigation of Influence of Diazepam, Valproate, Cyproheptadine and Cortisol on the Rewarding Ventral Tegmental Self-Stimulation Behaviour

    Investigation of Influence of Diazepam, Valproate, Cyproheptadine and Cortisol on the Rewarding Ventral Tegmental Self-Stimulation Behaviour

    Ind. J. Physio!. Pharmac., Volume 33, Number 3, 1989 INVESTIGATION OF INFLUENCE OF DIAZEPAM, VALPROATE, CYPROHEPTADINE AND CORTISOL ON THE REWARDING VENTRAL TEGMENTAL SELF-STIMULATION BEHAVIOUR SONTI V. RAMANA AND T. DESIRAJU· Department ofNeurophysiology, National Institute of Mental Health arzd Neuro Sciences, Bangalore - 560 029 ( Received on June IS, 1989 ) Abstract: Experiments were carried on in the Wistar rats having self-stimulation (88) electrodes implanted chronically in substantia nigra-ventral tegmental area (SN-VTA) to examine whether modulations of GABAergic, serotonergic, histaminergic, dopaminergic, and glucocorticoid neuronal receptor functions will affect or not the brain reward system and the 88 behaviour. The modulalon are the wellknown drugs: diazepam which is a facilitator ohome of the GABA recepton, and used clinically (or its tranquilising, anxiolytic, sedative-hypnotic and anti-convulsant properties: sodium valproate which is known to enhance the GABA synapse function, and used clinically for its anti­ convulsant property; haloperidol which is a dopaminergic receptor (D2) blocker, and clinically used for its anti-psychotic property; cyproheptadine which is both anti-histaminic and anti-serotonergic (blocka 5-HT2 receptor), used clinically for its antihistaminic and other beneficial properties; and hydrocortisone which is the stress-resisting glucocorticoid having direct effects on both brain and body cells, used clinically for the wide-ranging glucocorticoid therapeutic effects. The results revealed that systemic administration of these drugs, except haloperidol, caused no significant influenee on the 88 behaviour, thereby indicating that these nondopaminergic drugs have no effect on brain-reward system and also these categories of synaptic actions are not likely to be involved in the primary organization of the mechanisms of the brain-reward system.
  • 1493 JP XV Infrared Reference Spectra

    1493 JP XV Infrared Reference Spectra

    JP XV Infrared Reference Spectra 1493 Roxatidine Acetate Hydrochloride Preparation of sample: Potassium chloride disk method Roxithromycin Preparation of sample: Potassium bromide disk method Saccharin Preparation of sample: Potassium bromide disk method 1494 Infrared Reference Spectra JP XV Saccharin Sodium Hydrate Preparation of sample: Potassium bromide disk method Salbutamol Sulfate Preparation of sample: Potassium bromide disk method Santonin Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1495 Scopolamine Butylbromide Preparation of sample: Potassium bromide disk method Siccanin Preparation of sample: Potassium bromide disk method Sodium Fusidate Preparation of sample: Potassium bromide disk method 1496 Infrared Reference Spectra JP XV Sodium Picosulfate Hydrate Preparation of sample: Potassium bromide disk method Sodium Polystyrene Sulfonate Preparation of sample: Potassium bromide disk method Sodium Prasterone Sulfate Hydrate Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra 1497 Sodium Salicylate Preparation of sample: Potassium bromide disk method Sodium Valproate Preparation of sample: Liquid film method Spiramycin Acetate Preparation of sample: Potassium bromide disk method 1498 Infrared Reference Spectra JP XV Spironolactone Preparation of sample: Potassium bromide disk method Sulbactam Sodium Preparation of sample: Potassium bromide disk method Sulbenicillin Sodium Preparation of sample: Potassium bromide disk method JP XV Infrared Reference Spectra
  • Effect of Picrotoxin and Cyproheptadine Pretreatment On

    Effect of Picrotoxin and Cyproheptadine Pretreatment On

    Int J Biol Med Res. 2012; 3(2): 1606-1608 Int J Biol Med Res www.biomedscidirect.com Volume 2, Issue 4, Jan 2012 Contents lists available at BioMedSciDirect Publications International Journal of Biological & Medical Research BioMedSciDirect Journal homepage: www.biomedscidirect.com International Journal of Publications BIOLOGICAL AND MEDICAL RESEARCH Original article Effect of picrotoxin and cyproheptadine pretreatment on sodium valproate induced wet dog shake behavior in rats B M Sattigeri*, J J Balsara, J H Jadhav Department of pharmacology, Sumandeep Vidyapeeth’s SBKS & MIRC, Piparia, Vadodra Gujaart Department of pharmacology, Krishna Institute of Medical Sciences, Malkapur, Karad (Dist.Satara) 415110, Maharashtra, India A R T I C L E I N F O A B S T R A C T Keywords: Sodium valproate, a broad spectrum antiepileptic elevates the brain GABA levels by various Cyproheptadine mechanisms. Histological, electrophysiological and the biochemical studies suggest a Picrotoxin Sodium valproate regulatory role of GABA on dopaminergic neurons. Behavioral studies in animals provide an Wet Dog Shake Behavior additional evidence for interaction between GABAergic and DAergic systems. Valproate at 200- 500mg/kg induces Wet Dog Shake (WDS) behavior in rats. The WDS behavior in rats and head twitch responses in mice is evoked by 5- hydroxy-tryptophan (5-HT), the 5-HT precursor, the directly acting non-selective 5-HT receptor agonists and 5-HT releasers. In order to determine the involvement of GABAergic and 5-HTergic mechanism in the induction of WDS behavior by valproate in rats, the study was taken upto investigate the effect picrotoxin and cyproheptadine pretreatment on valproate induced WDS in rats.
  • Contraception and Misconceptions

    Contraception and Misconceptions

    CONTRACEPTION AND MISCONCEPTIONS CONTRACEPTION IN WOMEN WITH MENTAL ILLNESS OVERVIEW Hormones and mood How mental illness impacts on contraceptive choice Ideal contraception Pro and cons of contraceptive methods in women with mental illness Hormonal contraception and mood ESTROGENS anti-inflammatory neuroprotective effects of estradiol modulation of the limbic processing memory of emotionally-relevant information. estradiol “beneficially” modulates pathways implicated in the pathophysiology of depression, including serotonin and norepinephrine pathways PROGESTROGENS Previously thought to be anxiogenic, depressogenic Breakdown products Depression – alpha hydroxy progestrogen breakdown products pro – inflammatory, anxiogenic HORMONES AND MOODS – COMPLEX INTERPLAY MENTAL ILLNESS AND CONTRACEPTIVE CHOICE Effect of mental illness on contraceptive choice Effect of contraceptive choice on mental illness Drug interactions EFFECT MENTAL ILLNESS ON CONTRACEPTIVE CHOICE Impulsive Poor planning Cognitive and problem judgement Poor adherence IMPULSIVITY COGNITION POOR JUDGEMENT LETS NOT FORGET SUBSTANCES…… TYPES OF CONTRACEPTION No method Non hormonal Condom/Femidom Diaphragm Non hormone containing IUCD (Copper T) Hormonal COC POP Mirena Evra Patch Nuva Ring Implant ORAL CONTRACEPTIVES POP – avoid Same time every day COC Pros Effective Reduction PMS – monophasic estrogen dominant pill eg Femodene, Yaz, Nordette Cons Drug interactions Pill burden Daily dose EVRA PATCH Weekly patch Transdermal system: 150 mcg/day
  • 209627Orig1s000

    209627Orig1s000

    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 209627Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review Reviewers of Multi-Disciplinary Review and Evaluation SECTIONS OFFICE/ AUTHORED/ ACKNOWLEDGED/ DISCIPLINE REVIEWER DIVISION APPROVED Mark Seggel, Ph.D. OPQ/ONDP/DNDP2 Authored: Section 4.2 Digitally signed by Mark R. Seggel -S CMC Lead DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Mark R. Signature: Mark R. Seggel -S Seggel -S, 0.9.2342.19200300.100.1.1=1300071539 Date: 2018.08.08 16:29:15 -04'00' Frederic Moulin, DVM, PhD OND/ODE3/DBRUP Authored: Section 5 Pharmacology/ Digitally signed by Frederic Moulin -S Toxicology DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Reviewer Signature: Frederic Moulin -S 0.9.2342.19200300.100.1.1=2001708658, cn=Frederic Moulin -S Date: 2018.08.08 15:26:57 -04'00' Kimberly Hatfield, PhD OND/ODE3/DBRUP Approved: Section 5 Pharmacology/ Toxicology Digitally signed by Kimberly P. Hatfield -S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Team Leader Signature: Kimberly P. Hatfield -S 0.9.2342.19200300.100.1.1=1300387215, cn=Kimberly P. Hatfield -S Date: 2018.08.08 14:56:10 -04'00' Li Li, Ph.D. OCP/DCP3 Authored: Sections 6 and 17.3 Clinical Pharmacology Dig ta ly signed by Li Li S DN c=US o=U S Government ou=HHS ou=FDA ou=People Reviewer cn=Li Li S Signature: Li Li -S 0 9 2342 19200300 100 1 1=20005 08577 Date 2018 08 08 15 39 23 04'00' Doanh Tran, Ph.D.
  • Valproate-Olanzapine-Nifedipine Interaction Related Pedal Edema

    Valproate-Olanzapine-Nifedipine Interaction Related Pedal Edema

    Letter-to-the Editor Taiwanese Journal of Psychiatry (Taipei) Vol. 28 No. 3 2014 • 181 • Valproate-olanzapine-nifedipine Interaction Related Pedal Edema Patient’s bilateral pedal pitting edema did not Case Report resolve spontaneously after discontinuing olan- zapine until he received diuretics with furosemide A 45-year-old single male patient with bipo- 40 mg/day and spironolactone 75 mg/day on the lar I disorder was admitted to acute ward of our 21st day of pitting edema. He required further hospital due to depressive mood with irritability treatment, and had normal fi ndings in physical ex- for more than one month. The fi nding of physical amination and repeated laboratory tests. examination at admission revealed no bilateral pedal edema under long-term usage of valproate Comment 700 mg/day as mood stabilizer, nifedipine 30 mg/ day for essential hypertension, and allopurinol There have been some clinical reports to as- 100 mg/day for gouty arthritis before hospitaliza- sociate olanzapine treatment with bilateral lower tion. The results of laboratory tests for electro- extremity edema since 2000 [1]. Pre-clinical trials lytes, renal function, liver function, chest X-ray, of oral olanzapine (doses being equal or greater and electrocardiography were also within normal than 2.5 mg/day) have also reported peripheral limits. edema as a rare adverse event. The pathophysio- During this hospitalization, we added olan- logical mechanism of low extremity edema re- zapine 5 mg/day to control manic symptoms. Five mains unknown, although some mechanisms days later, he reported bilateral swelling over low- could be proposed, such as olanzapine’s blockage er legs and ankles, a bilateral 2+ pitting edema in of α1, M1, M3 and 5-HT2 receptors [2, 3].
  • U.S. Medical Eligibility Criteria for Contraceptive Use, 2016

    U.S. Medical Eligibility Criteria for Contraceptive Use, 2016

    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 65 / No. 3 July 29, 2016 U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................2 How to Use This Document ...............................................................................3 Keeping Guidance Up to Date ..........................................................................5 References ................................................................................................................8 Abbreviations and Acronyms ............................................................................9 Appendix A: Summary of Changes from U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 ...........................................................................10 Appendix B: Classifications for Intrauterine Devices ............................. 18 Appendix C: Classifications for Progestin-Only Contraceptives ........ 35 Appendix D: Classifications for Combined Hormonal Contraceptives .... 55 Appendix E: Classifications for Barrier Methods ..................................... 81 Appendix F: Classifications for Fertility Awareness–Based Methods ..... 88 Appendix G: Lactational
  • Relation Structure/Activité De Tanins Bioactifs Contre Les Nématodes

    Relation Structure/Activité De Tanins Bioactifs Contre Les Nématodes

    En vue de l'obtention du DOCTORAT DE L'UNIVERSITÉ DE TOULOUSE Délivré par : Institut National Polytechnique de Toulouse (INP Toulouse) Discipline ou spécialité : Pathologie, Toxicologie, Génétique et Nutrition Présentée et soutenue par : Mme JESSICA QUIJADA PINANGO le jeudi 17 décembre 2015 Titre : RELATION STRUCTURE/ACTIVITE DE TANINS BIOACTIFS CONTRE LES NEMATODES GASTROINTESTINAUX (HAEMONCHUS CONTORTUS) PARASITES DES PETITS RUMINANTS Ecole doctorale : Sciences Ecologiques, Vétérinaires, Agronomiques et Bioingénieries (SEVAB) Unité de recherche : Interactions Hôtes - Agents Pathogènes (IHAP) Directeur(s) de Thèse : M. HERVÉ HOSTE Rapporteurs : M. ADIBE LUIZ ABDALLA, UNIVERSIDAD DE SAO PAULO Mme HEIDI ENEMARK, NORWEGIAN VETERINARY INSTITUTE Membre(s) du jury : 1 M. FRANÇOIS SCHELCHER, ECOLE NATIONALE VETERINAIRE DE TOULOUSE, Président 2 M. HERVÉ HOSTE, INRA TOULOUSE, Membre 2 Mme CARINE MARIE-MAGDELAINE, INRA PETIT BOURG, Membre 2 M. SMARO SOTIRAKI, HAO-DEMETER, Membre 2 M. VINCENT NIDERKORN, INRA CLERMONT FERRAND, Membre QUIJADA J. 2015 Cette thèse est dédiée à mes parents, Teresa et Héctor, À mon mari, Rafäel, pour son soutien inconditionnel, son amour illimité, sa patience, sa loyauté, son amitié et surtout sa confidence, À ma grand-mère, Marcolina, car m'ait donné le plus grand et précieux cadeau en ma vie : ma foi en Dieu ma forteresse et mon espoir (Isaïas 41:13). À mes adorés sœurs, belle- sœurs et frère : Yurlin, Indira, Iskay, Olga, Zoraida et Jesus. Merci pour l’amour infini que m’ont toujours été donné, celui qu’a été prolongé par l'amour de mes merveilleux neveux. 1 QUIJADA J. 2015 REMERCIEMENTS Je remercie tout d’abord mon Dieu pour me donner le cadeau de la vie, et la forteresse pour vivre chaque jour.
  • WO 2018/002916 Al O

    WO 2018/002916 Al O

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/002916 Al 04 January 2018 (04.01.2018) W !P O PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C08F2/32 (2006.01) C08J 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, C08G 18/08 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/IL20 17/050706 HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (22) International Filing Date: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 26 June 2017 (26.06.2017) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 246468 26 June 2016 (26.06.2016) IL kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (71) Applicant: TECHNION RESEARCH & DEVEL¬ UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, OPMENT FOUNDATION LIMITED [IL/IL]; Senate TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, House, Technion City, 3200004 Haifa (IL).
  • Targeting Inflammatory Pathways by Flavonoids for Prevention and Treatment of Cancer

    Targeting Inflammatory Pathways by Flavonoids for Prevention and Treatment of Cancer

    1044 Reviews Targeting Inflammatory Pathways by Flavonoids for Prevention and Treatment of Cancer Authors Sahdeo Prasad, Kannokarn Phromnoi, Vivek R. Yadav, Madan M. Chaturvedi, Bharat B. Aggarwal Affiliation Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA Key words Abstract formation, tumor cell survival, proliferation, inva- l" cancer ! sion, angiogenesis, and metastasis. Whereas vari- l" inflammation Observational studies have suggested that life- ous lifestyle risk factors have been found to acti- l" flavonoids style risk factors such as tobacco, alcohol, high- vate NF-κB and NF-κB-regulated gene products, l" NF‑κB fat diet, radiation, and infections can cause cancer flavonoids derived from fruits and vegetables l" fruits l" vegetables and that a diet consisting of fruits and vegetables have been found to suppress this pathway. The can prevent cancer. Evidence from our laboratory present review describes various flavones, flava- and others suggests that agents either causing or nones, flavonols, isoflavones, anthocyanins, and preventing cancer are linked through the regula- chalcones derived from fruits, vegetables, le- tion of inflammatory pathways. Genes regulated gumes, spices, and nuts that can suppress the by the transcription factor NF-κB have been proinflammatory cell signaling pathways and shown to mediate inflammation, cellular trans- thus can prevent and even treat the cancer. Introduction cancers and the observed changes in the inci- ! dence of cancer in migrating populations. For ex- Despite spending billions of dollars in research, a ample, Ho [4] showed that although the Chinese great deal of understanding of the causes and cell in Shanghai will have a cancer incidence of 2 cases signaling pathways that lead to the disease, can- per 100 000 population, among those who mi- cer continues to be a major killer worldwide.